Participants
ESCC
PRIMARY TUMORS, LYMPH NODE METASTASES, SECONDARY, ONCOLOGY, METASTASES
In this single-center, single-arm, phase II trial, camrelizumab was combined with chemotherapy followed by surgery for locally advanced ESCC. Inclusion criteria were (1) stage II or III locally advanced resectable ESCC diagnosed before enrollment (2) no distant organ metastases or cervical lymph node metastases prior to enrollment (3) no secondary primary tumors (4) an Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 (5) no prior exposure to anticancer therapy, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy.